130 related articles for article (PubMed ID: 24384959)
1. [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Zhang Y; Zhao Q; Jiang Y; Yuan Z; Yang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 38(12):1223-7. PubMed ID: 24384959
[TBL] [Abstract][Full Text] [Related]
2. [Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Chen T; Chu ZH; Liu JP; Wang J; Zhao HY; Ou QJ
Ai Zheng; 2005 Aug; 24(8):1018-22. PubMed ID: 16086886
[TBL] [Abstract][Full Text] [Related]
3. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
[TBL] [Abstract][Full Text] [Related]
5. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
6. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
[TBL] [Abstract][Full Text] [Related]
7. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
Qiu F; Zhao X
J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
[TBL] [Abstract][Full Text] [Related]
8. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
9. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer.
Hirabayashi K; Okada E
Cancer; 1993 May; 71(9):2769-75. PubMed ID: 7682148
[TBL] [Abstract][Full Text] [Related]
12. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
14. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
Zanetta G; Fei F; Parma G; Balestrino M; Lissoni A; Gabriele A; Mangioni C
Ann Oncol; 1999 Oct; 10(10):1171-4. PubMed ID: 10586332
[TBL] [Abstract][Full Text] [Related]
16. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Ugurel S; Schadendorf D; Pföhler C; Neuber K; Thoelke A; Ulrich J; Hauschild A; Spieth K; Kaatz M; Rittgen W; Delorme S; Tilgen W; Reinhold U;
Clin Cancer Res; 2006 Sep; 12(18):5454-63. PubMed ID: 17000680
[TBL] [Abstract][Full Text] [Related]
18. Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.
Buxton EJ
Semin Oncol; 1992 Apr; 19(2 Suppl 5):9-17; discussion 17-8. PubMed ID: 1384148
[TBL] [Abstract][Full Text] [Related]
19. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix.
Herod J; Burton A; Buxton J; Tobias J; Luesley D; Jordan S; Dunn J; Poole CJ
Ann Oncol; 2000 Sep; 11(9):1175-81. PubMed ID: 11061615
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
